What is Sky Labs?
Founded in 2015, Sky Labs has established itself as a critical player in the digital health ecosystem. The company is best known for its flagship product, CART, a ring-type medical device engineered to detect Atrial Fibrillation with high clinical precision. By leveraging a proprietary algorithm that boasts a 98% accuracy rate, Sky Labs transforms continuous physiological data into actionable clinical insights. This preventative healthcare approach addresses the growing global demand for remote patient monitoring, positioning the company at the intersection of wearable technology, artificial intelligence, and cardiovascular diagnostics. As the firm scales, its focus remains on integrating these high-fidelity signals into broader healthcare networks to improve patient outcomes and reduce the burden on traditional clinical infrastructure.
How much funding has Sky Labs raised?
Sky Labs has raised a total of $34.3M across 2 funding rounds:
Series A
$4.3M
Series B
$30M
Series A (2019): $4.3M with participation from TBT
Series B (2021): $30M led by LB Investment, KB Investment, Soo Investment Capital, Atinum Investment, Moru Asset Management, and Korea Investment Partners
Key Investors in Sky Labs
LB Investment
A venture capital firm focused on transformative technologies that enhance human life, with a specific interest in deep-tech and healthcare innovation.
KB Investment
A long-standing South Korean venture capital and private equity firm that supports companies offering innovative technology, services, and entrepreneurship.
Korea Investment Partners
A prominent investment firm that provides strategic capital to high-growth enterprises, often focusing on industrial and environmental technology sectors.
What's next for Sky Labs?
With the support of major institutional backers, Sky Labs is poised to transition from a high-growth startup to a dominant force in the global medical device market. The current funding context suggests a strategic pivot toward international market expansion and the refinement of its diagnostic software suite. Future growth initiatives will likely prioritize regulatory approvals in new jurisdictions and the integration of its CART device into comprehensive telehealth platforms. By maintaining its focus on high-accuracy AF detection, the company is well-positioned to capitalize on the shift toward proactive, data-driven medicine, potentially exploring partnerships with global insurance providers and hospital networks to standardize its preventative monitoring protocols.
See full Sky Labs company page
